Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

Translational Respiratory Medicine

Table 2 Demographics in European series on EGFR mutations testing

Series	Year	Origin	N	Stages	Further description
Cortes-Funes et al. [10]	2005	Spain	83	Advanced	Failing 1st line/TKI therapy
Marchetti et al. [15]	2005	Italy	860	Stage I-II-III	Resection specimen
Rosell et al. [19]	2009	Spain	2105	Advanced	-
Penzel et al. [21]	2011	Germany	1047	All	-
Helland et al. [16]	2011	Norway	240	Stage I-II-III	Resection specimen
Vincenten et al. [20]	2012	Netherlands	810	All	-
Smits et al. [14]	2012	Netherlands	778	Advanced	-
Leary et al. [12]	2012	England	144	All	-
Pennycuick et al. [11]	2012	England	215	All	Non-squamous NSCLC
Vaguliene et al. [13]	2012	Lithuania	103	Advanced	Non-squamous NSCLC
Cadranel et al. [22]	2012	France	522	All	Failing 1st line/TKI therapy
This series	2012	Belgium	297	Advanced	ESMO guideline selected

N: number; TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; ESMO: European Society of Medical Oncology.